Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
Subtype terms (1)
More specific conditions that are subtypes of Liposarcoma in the MeSH hierarchy.
- Liposarcoma, Myxoid
18 drugs (13 approved, 5 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (9)
Phase 2 trials (63)
- fluorothymidine
- saracatinib
- dexrazoxane
- atezolizumab
- ridaforolimus
- apg-115
- avelumab
- urea
- irinotecan
- temsirolimus
- cixutumumab
- silmitasertib
- deoxycholic acid
- durvalumab
- eribulin
- efatutazone
- vismodegib
- gemcitabine
- lapatinib
- nivolumab
- ribociclib
- lenvatinib
- alisertib
- regorafenib
- olaratumab
- vincristine
- palbociclib
- mirdametinib
- ipilimumab
- sunitinib
- +33 more
Phase 1 trials (26)
- azacitidine
- anti-ny eso-1 tcr-transduced t cells
- autologous ny-eso-1-specific cd8-positive t lymphocytes
- fulvestrant
- aldesleukin
- id-lv305
- itacitinib
- ixazomib
- ny-eso-1-specific t cells
- cyclophosphamide
- autologous genetically modified mage a4c1032 t cells
- autologous genetically modified t cells, ny-eso-1c259 t
- vimseltinib
- Peposertib
- fludarabine
- sodium thiosulfate
- cisplatin
- letrozole
- tp-1287
- btx-a51
- agar t cells
- pf-07220060
- bbi-355
- pf-07224826
- nm32-2668
- okn4395
Organizations
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (59)
- Incyte
- Adaptimmune
- Daiichi Sankyo
- Bristol-Myers Squibb
- Merck
- Eli Lilly
- Genentech
- Pfizer
- Sanofi
- Novartis
- Ariad Pharmaceuticals
- CTI BioPharma
- GlaxoSmithKline
- Immune Design
- Infinity Pharmaceuticals, Inc.
- Mirati Therapeutics Inc.
- Concerto HealthAI
- Systems Medicine LLC
- National Institutes of Health (NIH)
- Javier Martín Broto, M.D.
- Centre Leon Berard
- Cornell University
- Harvard University
- Temple University
- Georgetown University
- University of Washington
- Grupo Espanol de Investigacion en Sarcomas
- Institut Bergonié
- Northwestern University
- Oregon Health and Science University
- +29 more
Organization Involved with Phase 1 Indications (10)